KR102167290B1 - Composition for preventing or treating prostatic diseases comprising Stauntonia hexaphylla extract and Cornus officinalis as active ingredients - Google Patents

Abstract

The present invention relates to a composition for the prevention or treatment of prostate disease containing a mulberry extract and cornus milk extract as an active ingredient, and specifically, the mulberry and cornus milk extract are not cytotoxic, androgen receptor, prostate specific antigen and prostate specific enzyme Since the effect of inhibiting the expression of is excellent, it can be used as an active ingredient in a composition for preventing or treating prostate disease.

Description

Composition for preventing or treating prostatic diseases comprising Stauntonia hexaphylla extract and Cornus officinalis as active ingredients, containing mulberry honey extract and cornus milk extract as active ingredients}

The present invention is a mulberry ( Stauntonia hexaphylla ) extract and cornus ( Cornus officinalis Sieb. et Zucc) extract as an active ingredient to a composition for preventing or treating prostate disease.

The prostate gland is an accessory gonad composed of glandular tissue and fibromyal tissue and plays a role in producing and secreting semen. Prostate fluid made in the prostate is made in the testis and supplies nourishment to the sperm that has been moved, and helps the sperm to actively exercise by maintaining a liquid state so that the ejaculated semen does not harden. Representative prostate-related diseases include enlarged prostate, prostate cancer and prostatitis.

Benign prostatic hyperplasia (BPH) is one of the most common diseases in adult men. It is reported that 50% of men over 50 and over 80% of men over 80 are affected, making it the highest frequency among male urinary tract disorders. do. The number of prostatic hyperplasia patients in Korea increased from about 459,000 in 2006 to 842,000 in 2011, an increase of 83.5%, and the incidence is rapidly increasing in recent years.

In general, the size of an adult's prostate is about 20g, but when the prostate is enlarged to an abnormal size and grows to a size of 40-400g, urinary frequency, nocturia, and strong and sudden urination of urinating more than 8 times a day by compressing the nearby urinary tract Symptoms of bladder storage such as unbearable urgency when urinating while feeling urinate, delayed urine in which urine is produced only when the urine flows, interruption in the flow of urine is interrupted, and symptoms of impaired discharge of the bladder, such as pressure during urination Will appear. Patients with prostatic hyperplasia do not need surgical treatment unless there is urinary tract obstruction or other complications, but about 50% of them by age 80 need treatment. In addition, some of the patients with prostatic hyperplasia are related to prostate cancer, and although it is not a fatal disease in itself, it is emerging as an important medical problem in the current society entering an ultra-aging society in that it lowers the quality of life.

The treatment method for prostatic hyperplasia was almost performed in the early stage, but from the late 1980s, the method of drug administration has rapidly changed. However, conventional drugs used in the treatment of prostatic hyperplasia exhibit many side effects and have limitations in their efficacy, and thus it is necessary to develop a new therapeutic agent that does not cause side effects or drug resistance and has excellent therapeutic effects.

Prostate cancer is the most common cancer among male cancers in the West and shows a high incidence, and the frequency is rapidly increasing even in Korea. The treatment of prostate cancer varies depending on the stage of the disease. For local cancer, treatment is performed for the purpose of fundamental treatment, but for metastatic cancer, systemic treatment is performed. For the treatment of localized prostate cancer, atmospheric therapy, radical prostatectomy, and radiation therapy can be selected in consideration of the patient's age, health status, sexual function status, tumor stage and degree of differentiation, and patient preference. For metastatic prostate cancer, hormone therapy or chemotherapy can be performed.

Prostatitis is a disease in which the prostate is inflamed, and it is so common that about 50% of adult men experience symptoms at least once in their lifetime. In the case of urinary tract infection, bacteria are most often directly infected through the urethra, and in addition, it can be caused by impaired excretion of prostate fluid, urinary reflux into the prostate, and transmission of inflammation such as hemorrhoids or colitis.

Since prostate diseases such as prostate cancer, prostatic hyperplasia, and prostatitis are associated with androgens, which is a male hormone, anti-androgen drugs that inhibit the expression of androgen receptors can provide treatment and prevention effects or alleviate symptoms. . In addition, prostate-specific antigen inhibitors that inhibit the expression of prostate-specific antigens are also effective in preventing and treating/sympting prostate diseases affected by prostate-specific antigens. In addition, 5-alpha reductase inhibitors, which inhibit male hormones, are used in the treatment of male diseases caused by male hormones, such as prostatic hypertrophy and hair loss. More specifically, 5-alpha reductase, which converts testosterone, a male hormone into dihydrotestosterone (DHT), is a NADPH-dependent 3-oxo-5α-steroid-dehydrogenase of microsomes, which is a double like testosterone. Reduce binding steroids. 5-alpha reductase has subtypes of type 1, type 2, and type 3, and type 1 is mainly present in various organs such as skin and liver tissue, and type 2 is mainly present in the urogenital tract including liver and prostate. Testosterone is converted to more than 90% dihydrotestosterone by 5-alpha reductase in the prostate tissue, and dihydrotestosterone promotes prostate growth with approximately 10 times more activity than testosterone. Therefore, when the 5-alpha reductase is efficiently inhibited, the synthesis of dihydrotestosterone, which has strong physiological activity, is reduced, and eventually, an enlarged prostate can be improved or treated. In addition, as in prostatic hyperplasia, when dihydrotestosterone is excessively synthesized by 5-alpha reductase, dihydrotestosterone binds to androgen receptors around the hair follicle, gradually shrinking and deteriorating the hair follicle, resulting in hair loss. Therefore, it is possible to improve or treat hair loss by effectively inhibiting 5-alpha reductase.

On the other hand, mul-honey can be found in valleys or forests in southern regions such as Jeonnam, Gyeongnam, and Chungnam in Korea. It is an evergreen vine plant in the family Creeping vine and its scientific name is Stauntonia Hexaphylla. Stems, leaves, and roots are used as medicinal materials, and are known to have excellent anti-inflammatory, antipyretic, and analgesic effects. It is also used as a cardiac medicine used to return the function to normal when the heart is weak or incomplete, or as a diuretic that promotes the excretion of unnecessary water in the body. In addition, it is known to be effective in suppressing subcutaneous fat accumulation, joint disease, uterine fibroids, and facial neuralgia.

Cornus (Corni Fructus) originated from Cornus officinalis Siebold et Zuccarini (Cornaceae) ripe fruit with seeds removed. Irregular flakes or pockets, 10 to 15 mm long and 1 cm wide. The outer surface is dark reddish-purple to dark purple, with glossy and rough wrinkles. On the flesh, there is a mark from which seeds are removed, there is a mark on the top of the calyx, and a mark on the bottom of the fruit stem. The quality is soft, there is a slight odor, and the taste is sour and a little sweet. Cornus milk exhibits diuretic, blood pressure lowering, nourishing, anti-allergic, antihistamine, antiacetylcholine, and antibarium effects, and is known to have antimicrobial (antifungal) effects.

Accordingly, the present inventors endeavored to develop a natural product-derived prostate disease therapeutic agent that is safe and has no side effects. As a result, the complex extracts of mulberry and cornus milk have no cytotoxicity, and the effect of inhibiting the expression of androgen receptor, prostate specific antigen and prostate specific enzyme By confirming the excellence and revealing that it can be used as an active ingredient of a composition for preventing or treating prostate disease, the present invention was completed.

Republic of Korea Patent Publication No. 10-2016-0143500

An object of the present invention is Stauntonia hexaphylla ) extract and cornus ( Cornus officinalis Sieb. et Zucc) extract as an active ingredient, to provide a composition for preventing or treating prostate disease.

In order to achieve the above object, the present invention is a mul honey ( Stauntonia hexaphylla ) extract and cornus ( Cornus officinalis Sieb. et Zucc) It provides a pharmaceutical composition for preventing or treating prostate disease, containing the extract as an active ingredient.

In addition, the present invention provides a health food for the prevention or improvement of prostate disease, containing the mulberry extract and cornus milk extract as active ingredients.

In addition, the present invention provides a food composition for preventing or improving prostate disease, containing mulleul honey extract and cornus milk extract as active ingredients.

The complex extract of mulberry and cornus milk of the present invention has no cytotoxicity, and has excellent inhibitory effect on the expression of androgen receptor, prostate-specific antigen and prostate-specific enzyme, and thus can be used as an active ingredient of a composition for preventing or treating prostate disease.

FIG. 1 is an extract of Stauntonia hexaphylla prepared in an example of the present invention in LNCaP cells, Cornus officinalis Sieb. et Zucc) is a diagram showing cytotoxicity after treatment with 0, 10, 25, and 50 ㎍/㎖ of the extract, or the mulberry and cornus milk complex extract, respectively.
FIG. 2 is an AR after treatment with 25 μM of testosterone and 1 μM of testosterone in LNCaP cells prepared in an example of the present invention with 25 μg/ml of mulberry extract, 50 μg/ml of cornus milk extract, or 25 μg/ml of a mulberry and cornus milk extract , PSA and 5α-reductase 2 is a diagram confirming the protein expression changes.

Hereinafter, the present invention will be described in more detail.

The present invention is a mulberry ( Stauntonia It provides a pharmaceutical composition for preventing or treating prostate disease, containing hexaphylla ) extract and cornus ( Cornus officinalis Sieb. et Zucc) extract as an active ingredient.

Each of the mulberry extract and cornus milk extract, which are active ingredients of the present invention, is preferably prepared by a method comprising the following steps, but is not limited thereto:

1) extracting by adding an extraction solvent to each of mul honey and cornus milk;

2) filtering the extract of step 1);

3) concentrating the filtrate of step 2) under reduced pressure; And

4) drying the concentrate of step 3).

In the production method of the present invention, the mulberry or cornelian milk of step 1) may be grown or commercially available without limitation. In addition, the mulchk may be used as mulchk flowers, branches, stems, leaves, fruits, above-ground parts, rhizomes, roots, or a combination thereof, and more specifically mulchk leaves.

In the production method of the present invention, it is preferable to use water, alcohol or a mixture thereof as the extraction solvent in step 1). It is preferable to use a C ₁ to C ₂ lower alcohol as the alcohol, and it is preferable to use ethanol or methanol as the lower alcohol. The extraction method is preferably shaking extraction, Soxhelt extraction, or reflux extraction, but is not limited thereto. It is preferable to extract by adding 1 to 20 times the amount of dried mulberry or cornelian oil to the extraction solvent, more preferably to extract by adding 3 to 17 times, and even more preferably to extract by adding 5 to 15 times . The extraction temperature is preferably 10 to 100, but is not limited thereto. In addition, the extraction time is preferably 1 to 72 hours, but is not limited thereto. In addition, the number of extractions is preferably 1 to 5 times, more preferably 3 to 4 times of repeated extraction, and even more preferably 3 times, but is not limited thereto.

In the manufacturing method of the present invention, the vacuum concentration in step 3) is preferably a vacuum vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably vacuum drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.

In the manufacturing method of the present invention, the mulberry extract and cornus milk extract may be mixed after preparing each extract, but may also be prepared in a form in which an extract thereof is obtained after mixing mulberry and cornus milk.

The composition may contain mulberry extract: cornus milk extract in a weight ratio of 5: 5 to 9.5: 0.5, specifically 6: 4 to 9.5: may contain in a weight ratio of 0.5, more specifically 7: 3 to 9.5: It may be contained in a weight ratio of 0.5, more specifically 8: 2 to 9.5: may be contained in a weight ratio of 0.5, and even more specifically 8.5: 2.5 to 9.5: may be contained in a weight ratio of 0.5.

The prostate disease may be, for example, prostate cancer, prostatic hyperplasia or prostatitis.

In a specific embodiment of the present invention, the present inventors prepared a mulberry leaf 70% alcohol extract and cornus milk 70% alcohol extract, and mixed the extracts at various mixing ratios to prepare a mulberry and cornus milk complex extract.

In addition, the present inventors confirmed the cytotoxicity of the complex extract of mulberry and cornus milk in prostate cancer cells, and it was confirmed that the complex extract had no cytotoxicity at various concentrations (see FIG. 1).

In addition, the present inventors confirmed the protein expression of androgen receptor (AR), prostate-specific antigen (PSA) and prostate-specific enzyme (5α-reductase 2) in prostate cancer cells treated with the mulberry and cornelian milk complex extract with testosterone, It was confirmed that the complex extract had excellent inhibitory effect on protein expression of AR, PSA and 5α-reductase 2 (see FIG. 2).

Therefore, the present inventors confirmed that the complex extract of mulberry and cornus milk of the present invention is non-cytotoxic and has an excellent inhibitory effect on the expression of androgen receptor, prostate-specific antigen and prostate-specific enzyme. It can be usefully used as an active ingredient in a pharmaceutical composition for prophylaxis or treatment, or a pharmaceutical composition for preventing or treating male diseases caused by testosterone, such as hair loss.

The composition of the present invention can be administered orally or parenterally (eg, application or intravenous, subcutaneous, intraperitoneal injection). Formulations for non-administration include powders, granules, tablets, capsules, sterilized aqueous solutions, solutions, non-aqueous solutions, suspensions, emulsions, syrups, suppositories, aerosols, and other external preparations and sterile injectables according to conventional methods. It may be formulated and used, and preferably, a pharmaceutical composition for skin external use such as cream, gel, patch, spray, ointment, warning agent, lotion, linerment, pasta or cataplasma may be prepared and used. , But is not limited thereto. Compositions for topical administration may be anhydrous or aqueous, depending on the clinical prescription. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like may be used. Solid preparations for oral administration include powders, granules, tablets, capsules, soft capsules, pills, and the like. Liquid preparations for oral use include suspensions, solvents, emulsions, syrups, aerosols, etc.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as humectants, sweeteners, fragrances, and preservatives are included. I can.

The composition may be prepared by including one or more pharmaceutically acceptable carriers in addition to the active ingredient of the present invention for administration. Pharmaceutically acceptable carriers can be used by mixing saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and one or more of these components, and if necessary, antioxidants and buffers , Other conventional additives such as bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to form an injectable formulation such as an aqueous solution, suspension, or emulsion.

It is preferable that the pharmaceutically acceptable additive according to the present invention is included in an amount of 0.1 to 90 parts by weight based on the composition.

The preferred dosage of the composition of the present invention depends on the degree of absorption of the active ingredient in the body, the age, sex, and degree of obesity of the patient, but may be appropriately selected by those skilled in the art. However, for a desirable effect, in the case of oral administration, the composition of the present invention per 1 kg of body weight per day to adults is generally 0.0001 to 500 mg/kg per day, preferably 0.001 to 300 mg/kg, more preferably It is recommended to administer 0.01 to 200 mg/kg. Administration may be administered once a day, or may be divided several times. The above dosage does not in any way limit the scope of the present invention.

In addition, the present invention provides a health food for the prevention or improvement of prostate disease, containing the mulberry extract and cornus milk extract as active ingredients.

In addition, the present invention provides a food composition for preventing or improving prostate disease, containing mulleul honey extract and cornus milk extract as active ingredients.

The mulberry extract and cornus milk extract, mixing ratios thereof, and prostate disease are the same as the description of the pharmaceutical composition for preventing or treating prostate disease, and the specific description refers to the above, and hereinafter, specific to health food or food composition Only the configuration will be described.

On the other hand, since it was confirmed that the complex extract of mulberry and cornus milk of the present invention has no cytotoxicity and has excellent inhibitory effect on the expression of androgen receptor, prostate-specific antigen and prostate-specific enzyme, the complex extract of the present invention is used for preventing or improving prostate disease. It can be usefully used as an active ingredient in food or food composition. In addition, the complex extract of the present invention can be usefully used as an active ingredient in a health food or food composition for preventing or improving male diseases caused by testosterone, such as hair loss.

The two extracts of the present invention can be provided as a health food or a food composition by mixing with a food pharmaceutically acceptable carrier.

The health food of the present invention includes forms such as tablets, capsules, pills or liquids.

When using the two extracts of the present invention as a food or beverage additive, the two extracts are added as they are or used together with other food or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the two extracts may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment). In the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, the two extracts can be taken for a long time because there is no problem in terms of safety. There is no particular limitation on the type of food.

Examples of foods to which the above substances can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, and drinks. , Alcoholic beverages and vitamin complexes. When formulated as a beverage, the liquid component added in addition to the above two extracts is not limited anymore, but may contain various flavoring agents or natural carbohydrates as an additional component, such as a conventional beverage. Examples of the natural carbohydrates described above are monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.) and polysaccharides (e.g., common sugars such as dextrin, cyclodextrin, etc.), and xylitol. , Sorbitol, and sugar alcohols such as erythritol. The proportion of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 12 g per 100 mL of the composition of the present invention. As flavoring agents other than those described above, natural flavoring agents [taumarin, stevia extract (eg, rebaudioside A, glysirhizin, etc.)] and synthetic flavoring agents (eg, saccharin, aspartame, etc.) can be used. .

In addition, the food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavors and natural flavoring agents, coloring agents and enhancers (cheese, chocolate, etc.), pectic acid and its salts, organic acids, protection It may contain a colloidal thickener, a pH adjuster, a stabilizer, a preservative, a glycerin, an alcohol, a carbonate used in carbonated beverages, and the like. In addition, the food composition of the present invention may contain pulp for the production of fruit and vegetable beverages. These components may be used alone or in combination, and the proportion of these additives is generally selected from 0.001 to 50 parts by weight per total weight of the composition.

Hereinafter, the present invention will be described in detail by Examples, Experimental Examples and Preparation Examples.

However, the following Examples, Experimental Examples, and Preparation Examples are merely illustrative of the present invention, and the contents of the present invention are not limited to the following Examples, Experimental Examples, and Preparation Examples.

< Example 1> Mulberry Preparation of extract

Dry mulberry ( Stauntonia hexaphylla ) 300 mL of 70% alcohol was added to 20 g of leaves and extracted at low temperature for 12 hours by sonication. Then, the obtained extract was filtered through a filter paper, and the filtered residue was extracted at low temperature with 300 mL of 70% alcohol for 12 hours, and the process of filtering was repeated additionally twice. When the extraction was completed, the filtrate was combined, concentrated under reduced pressure, and freeze-dried to obtain a mulberry extract.

< Example 2> Preparation of cornus milk extract

Dry cornus ( Cornus officinalis Sieb. et Zucc) 300 mL of 70% alcohol was added to 20 g and extracted at low temperature for 12 hours by sonication. Then, the obtained extract was filtered through a filter paper, and the filtered residue was extracted at low temperature with 300 mL of 70% alcohol for 12 hours, and the process of filtering was repeated an additional two times. When the extraction was completed, the filtrate was combined, concentrated under reduced pressure, and freeze-dried to obtain a cornus milk extract.

< Example 3> Mulberry And preparation of cornus milk complex extract

Mul-honey and corn-su-milk complex extracts were prepared by mixing the mulberry extract obtained in <Example 1> and the cornus milk extract obtained in <Example 2> at the mixing ratio shown in Table 1 below.

Example
Extract mix ratio Mulberry: Cornus 3-1 5: 5 3-2 6: 4 3-3 7: 3 3-4 8: 2 3-5 9: 1

< Experimental example 1> Mulberry And cytotoxicity of cornus milk extract

In order to investigate the cytotoxicity of the mulberry and cornus milk extracts, the cell viability was confirmed after treatment with the mulberry and cornus milk extract on prostate cancer cells.

Specifically, LNCaP cells (ATCC, USA), a male hormone-dependent human prostate cancer cell line, were cultured in RPMI-1640 medium (Gibco) containing 10% FBS (fetal bovine serum) at 37° C. and 5% CO ₂ . The cultured cells were dispensed into a 96-well plate at a concentration of 1×10 ⁴ cells/well, and cultured under the same conditions as the above conditions for 18 hours. Then, in the cultured cells, the mulch honey extract prepared in <Example 1>, the cornus milk extract prepared in <Example 2>, or the mulch honey and cornus milk composite extract prepared in <Example 3> were respectively 0 and 10 , After treatment at a concentration of 25 or 50 µg/ml and incubation for an additional 72 hours, a cell viability assay kit (EX-cytox; DaeiLab Service, Korea) was added according to the manufacturer's procedure, and then 450 using an ELISA reader. The absorbance was measured at nm and graphed.

As a result, as shown in Fig. 1, it was confirmed that the complex extract of mulberry and cornus milk had no cytotoxicity.

< Experimental example 1> Mulberry And PSA, AR and 5α- of cornus milk complex extract reductase 2 Confirmation of protein expression inhibitory effect

In order to find out whether the complex extract of mulberry and cornus milk is effective in the treatment of prostate disease, testosterone, mulberry and cornus milk extract were treated on prostate cancer cells, and then androgen receptor (AR), prostate specific antigen (PSA), and prostate specific. Protein expression of the enzyme (5α-reductase 2) was confirmed.

Specifically, LNCaP cells (ATCC, USA) were dispensed into a 6-well plate at a concentration of 5×10 ⁴ cells/well, and cultured at 37° C. for 18 hours. Then, the cultured cells were treated with 1 μM of testosterone, and at the same time 25 or 50 μg/ml of the mulberry extract prepared in <Example 1>, 50 μg/ml of the cornus milk extract prepared in <Example 2>, or the above After treatment at a concentration of 50 µg/ml of the mul-honey and cornus milk complex extract prepared in Example 3, it was further cultured for 72 hours, and then collected. As a positive control (BPH), only 1 μM of testosterone was treated without any extract, and as a control (Fina), 10 μM of Finasteride, a treatment for prostatic hyperplasia, was treated with 1 μM of testosterone instead of the extract. In addition, as a control group (saw pal), 100 µg/ml of Saw Palmetto, a treatment for prostatic hyperplasia, was treated with 1µM of testosterone instead of the extract. The untreated group was used as a negative control group (Control).

Treated cells collected after culture with RIPA buffer (50 mM Tris-HCl, pH 8.0, with 150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate, with a protease inhibitor cocktail) And centrifuged at a speed of 12,000 rpm for 20 minutes to separate proteins. The isolated protein was quantified by the BCA (Bicinchoninic acid) method.

Of the quantified proteins, 10 µg was treated on an SDS-PEGE gel, subjected to electrophoresis, and then transferred to a PVDF membrane. After that, the PVDF membrane was reacted with 5% skim milk for about 1 hour to remove nonspecific binding proteins on the surface, and the primary antibodies were anti-AR antibody, anti-PSA antibody, anti-5α-reductase 2 antibody, And it was reacted for one day at 4°C using an anti-β-actin antibody. After that, the secondary antibody was treated at room temperature for 1 hour, and protein expression of AR, PSA and 5α-reductase 2 was confirmed and graphed using an ECL kit (Amersham, UK).

As a result, as shown in FIG. 2, the inhibitory effect of AR and PSA protein expression in the cell group treated with 25 µg/ml of the mulberry and cornus milk extract compared to the cell group treated with 25 or 50 µg/ml alone It was confirmed that is remarkably excellent. In addition, it was confirmed that the inhibitory effect of AR and PSA protein expression was more excellent in the cell group treated with the mulberry and cornus milk extracts mixed at a mixing ratio of 9:1. In addition, it was confirmed that the 5a-reductase 2 protein expression inhibitory effect was excellent in the cell group treated with the mulberry and cornus milk extract.

Hereinafter, examples of preparation for the composition of the present invention are illustrated.

<Production Example 1> Preparation of pharmaceutical formulation

<1-1> Preparation of powder

10 mg of the complex extract of the present invention

1 g lactose

The above ingredients were mixed and filled in an airtight cloth to prepare a powder.

<1-2> Preparation of tablets

0.1 mg of the complex extract of the present invention

100 mg corn starch

100 mg lactose

2 mg of magnesium stearate

After mixing the above ingredients, tablets were prepared by tableting according to a conventional tablet preparation method.

<1-3> Preparation of capsules

0.1 mg of the complex extract of the present invention

100 mg corn starch

100 mg lactose

2 mg of magnesium stearate

After mixing the above ingredients, the gelatin capsules were filled according to a conventional capsule preparation method to prepare a capsule formulation.

<1-4> Preparation of ring

1 mg of the complex extract of the present invention

1.5 g lactose

1 g glycerin

0.5 g xylitol

After mixing the above components, it was prepared so as to be 4 g per pill according to a conventional method.

<1-5> Preparation of granules

0.15 mg of the complex extract of the present invention

50 mg soybean extract

200 mg glucose

600 mg starch

After mixing the above ingredients, 100 mg of 30% ethanol was added and dried at 60° C. to form granules and then filled into a cloth.

<Production Example 2> Preparation of health food

Foods containing the complex extract of the present invention as an active ingredient were prepared as follows.

<2-1> Preparation of flour food

0.5 to 5.0 parts by weight of the complex extract of the present invention was added to flour, and bread, cakes, cookies, crackers and noodles were prepared using this mixture.

<2-2> soup And the production of gravies

0.1 to 5.0 parts by weight of the complex extract of the present invention was added to soups and juices to prepare health-promoting meat products, noodles soup, and juice.

<2-3> Ground Of ground beef Produce

Ground beef for health promotion was prepared by adding 10 parts by weight of the complex extract of the present invention to ground beef.

<2-4> Manufacture of dairy products

5 to 10 parts by weight of the complex extract of the present invention was added to milk, and various dairy products such as butter and ice cream were prepared using the milk.

<2-5> Linear Produce

Brown rice, barley, glutinous rice, and adlay were gelatinized by a known method, dried, and then roasted, and then prepared into a powder having a particle size of 60 mesh with a grinder.

Black soybeans, black sesame seeds, and perilla seeds were also steamed and dried by a known method, and then roasted, and then prepared into powder having a particle size of 60 mesh with a grinder.

The composite extract of the present invention was concentrated under reduced pressure in a vacuum concentrator, sprayed and dried with a hot air dryer, and the resulting dried product was pulverized with a grinder to a particle size of 60 mesh to obtain a dry powder.

It was prepared by blending the grains, seeds and the complex extract of the present invention prepared above in the following ratio.

Grains (30 parts by weight of brown rice, 15 parts by weight of barley, 20 parts by weight of barley),

Seeds (perilla 7 parts by weight, black beans 8 parts by weight, black sesame 7 parts by weight),

Complex extract of the present invention (3 parts by weight),

Ganoderma lucidum (0.5 parts by weight),

Rehmannia (0.5 parts by weight)

< Manufacturing example 3> Health drink Produce

<3-1> Health drink Produce

Subsidiary materials such as liquid fructose (0.5%), oligosaccharide (2%), sugar (2%), salt (0.5%), water (75%) and 0.5 g of the complex extract of the present invention are homogeneously mixed to perform instant sterilization. Then, it was prepared by packaging it in a small container such as a glass bottle or a plastic bottle.

<3-2> Preparation of vegetable juice

Vegetable juice was prepared by adding 0.5 g of the complex extract of the present invention to 1,000 mL of tomato or carrot juice.

<3-3> Preparation of fruit juice

Fruit juice was prepared by adding 0.1 g of the complex extract of the present invention to 1,000 mL of apple or grape juice.

Claims (9)

Containing mulberry ( Stauntonia hexaphylla ) extract and cornus ( Cornus officinalis Sieb. et Zucc) extract as active ingredients,
The extract will extract into a lower alcohol, or a mixed solvent of water and a lower alcohol of C ₁ to C ₂ of the C ₁ to C _2,
Mulle honey extract: a pharmaceutical composition for the prevention or treatment of prostate disease containing the cornus milk extract in a weight ratio of 6: 4 to 9.5: 0.5.
delete The pharmaceutical composition for preventing or treating prostate disease according to claim 1, wherein the C ₁ to C ₂ lower alcohol is methanol or ethanol.
The pharmaceutical composition for preventing or treating prostate disease according to claim 1, wherein the extract is any one or more extracts selected from flowers, branches, stems, leaves, fruits, ground parts, rhizomes, and roots.
delete delete The pharmaceutical composition for preventing or treating prostate disease according to claim 1, wherein the prostate disease is an enlarged prostate.
Contains mulberry honey extract and cornus milk extract as active ingredients,
The extract will extract into a lower alcohol, or a mixed solvent of water and a lower alcohol of C ₁ to C ₂ of the C ₁ to C _2,
Mulle Honey Extract: Cornus milk extract containing a weight ratio of 6: 4 to 9.5: 0.5, health food for preventing or improving prostate disease.
Contains mulberry honey extract and cornus milk extract as active ingredients,
The extract will extract into a lower alcohol, or a mixed solvent of water and a lower alcohol of C ₁ to C ₂ of the C ₁ to C _2,
Mulle Honey Extract: Cornus milk extract containing a weight ratio of 6: 4 to 9.5: 0.5, a food composition for preventing or improving prostate disease.

Images